PHARMGIANT SINOVAC IS INTERESTED IN LOCALIZATION OF VACCINES IN KAZAKHSTAN

February 14, 2023 - SK-Pharmacy, a single distributor, held a meeting with representatives of the Chinese pharmaceutical giant Sinovac Biptech LTD.

The biopharmaceutical company is engaged in the research, development, production and commercialization of vaccines against infectious diseases.

The meeting was attended by Sinovac - Director for International Business Development in the European Region Igor Mozolevich and Sales Manager in the European Region Siqi Feng.

Sinovac expressed interest in discussing the possibility of localizing vaccines on the territory of the Republic of Kazakhstan and shared information on the product line.

Focusing on the Chinese market, Sinovac continues to look for opportunities in international markets. Sinovac has established reliable partnerships with dozens of countries around the world, where they have received licenses to sell their products, including COVID-19 vaccine, inactivated hepatitis and HIV vaccine.

Sinovac's commercial vaccines are Healive (for hepatitis A), Bilive (combined for hepatitis A and B, Anflu (for influenza), Panflu (for H5N1) and PANFLU.1 (for H1N1), as well as the universal pandemic influenza vaccine and the vaccine against Japanese encephalitis.

In addition, vaccines against enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies.

Its subsidiary Tangshan Yian conducts field trials of self-developed inactivated rabies vaccines for animals.

And in mid-April 2020, China approved a clinical trial for a COVID-19 vaccine developed by Sinovac. The vaccine, called CoronaVac, is an inactivated whole virus vaccine against COVID-19.

Recall, the Head of State noted the importance of cooperation with global pharmaceutical corporations, attracting investors, ensuring the transfer of technologies and the latest developments.

For Kazakhstan, the transfer of modern technologies, the introduction and the availability of its own localized sites are extremely important. The well-established domestic production of vaccines will significantly affect the stabilization of the epidemiological situation in the country.

As part of the implementation of measures to develop the pharmaceutical industry in Kazakhstan, the Single Distributor holds meetings with major players in the global pharmaceutical industry, during which their long-term plans for presence in the Kazakh pharmaceutical market and investment in the industry are discussed.

During the discussion, the possibilities for using the mechanisms of long-term agreements, direct contracts were also voiced. In addition, the issue of the possibility of creating vaccine hubs for nearby countries was discussed.

Following the meeting, it was noted that it is necessary to consolidate joint efforts for the purpose of mutually beneficial cooperation. The parties expressed confidence that today's dialogue will definitely continue and bring mutually beneficial results.

Reference:
Sinovac Biotech Ltd. is a Chinese biopharmaceutical company. The company is based in Beijing.

The cumulative global sales of Sinovac Biptech LTD. amount to almost 160 million doses. In 2019, an average of 112 people per minute were vaccinated with Sinovac vaccines for immune protection.

In mid-April 2020, China approved a clinical trial for a COVID-19 vaccine developed by Sinovac.